Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251401 | 0.89 | MEN1 (0.43) | MEN1KMT2APPARGLMNA | |
| SCHEMBL24251371 | 0.89 | KMT2A (0.41) | ROCK2ROCK1MAPTGUCY1B2GUCY1A2 | |
| SCHEMBL24251412 | 0.87 | MEN1 (0.46) | ROCK2ROCK1MAPTMEN1KMT2A | |
| SCHEMBL24251376 | 0.84 | KMT2A (0.39) | ROCK2ROCK1MAPTGUCY1B2GUCY1A2 | |
| SCHEMBL24251556 | 0.83 | PDE2A (0.43) | ROCK2ROCK1MAPTMEN1KMT2A | |
| SCHEMBL24251388 | 0.83 | PDE2A (0.43) | ROCK2ROCK1MAPTMEN1KMT2A | |
| SCHEMBL24251422 | 0.82 | ALDH1A1 (0.46) | ROCK2ROCK1MAPTMEN1KMT2A | |
| SCHEMBL24251582 | 0.80 | PPARG (0.46) | ROCK1PPARGLMNAALDH1A1 | |
| SCHEMBL24251378 | 0.80 | IMPDH2 (0.37) | MAPTRIPK1PPARGLMNAALDH1A1 | |
| SCHEMBL23355438 | 0.79 | PDE4B (0.35) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | ROCK2 3807/4885ROCK1 3815/4885MAPT 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.